JP2024075676A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024075676A5 JP2024075676A5 JP2024043606A JP2024043606A JP2024075676A5 JP 2024075676 A5 JP2024075676 A5 JP 2024075676A5 JP 2024043606 A JP2024043606 A JP 2024043606A JP 2024043606 A JP2024043606 A JP 2024043606A JP 2024075676 A5 JP2024075676 A5 JP 2024075676A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- composition
- variable domain
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19192327.5 | 2019-08-19 | ||
| EP19192327 | 2019-08-19 | ||
| JP2022511055A JP7536085B2 (ja) | 2019-08-19 | 2020-08-19 | Ｌｇｒ５及びｅｇｆｒに結合する抗体とトポイソメラーゼｉ阻害剤との組合せを用いる癌の治療 |
| PCT/NL2020/050517 WO2021034194A2 (en) | 2019-08-19 | 2020-08-19 | Treatment of cancer with a combination of an antibody that binds lgr5 and egfr and a topoisomerase i inhibitor. |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022511055A Division JP7536085B2 (ja) | 2019-08-19 | 2020-08-19 | Ｌｇｒ５及びｅｇｆｒに結合する抗体とトポイソメラーゼｉ阻害剤との組合せを用いる癌の治療 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026023076A Division JP2026077781A (ja) | 2019-08-19 | 2026-02-16 | Ｌｇｒ５及びｅｇｆｒに結合する抗体とトポイソメラーゼｉ阻害剤との組合せを用いる癌の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024075676A JP2024075676A (ja) | 2024-06-04 |
| JP2024075676A5 true JP2024075676A5 (enExample) | 2024-09-30 |
Family
ID=67659296
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022511055A Active JP7536085B2 (ja) | 2019-08-19 | 2020-08-19 | Ｌｇｒ５及びｅｇｆｒに結合する抗体とトポイソメラーゼｉ阻害剤との組合せを用いる癌の治療 |
| JP2024043606A Pending JP2024075676A (ja) | 2019-08-19 | 2024-03-19 | Ｌｇｒ５及びｅｇｆｒに結合する抗体とトポイソメラーゼｉ阻害剤との組合せを用いる癌の治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022511055A Active JP7536085B2 (ja) | 2019-08-19 | 2020-08-19 | Ｌｇｒ５及びｅｇｆｒに結合する抗体とトポイソメラーゼｉ阻害剤との組合せを用いる癌の治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230084382A1 (enExample) |
| EP (1) | EP4017879A2 (enExample) |
| JP (2) | JP7536085B2 (enExample) |
| KR (1) | KR20220048015A (enExample) |
| CN (2) | CN114555115A (enExample) |
| AU (1) | AU2020331879C1 (enExample) |
| BR (1) | BR112022003143A2 (enExample) |
| CA (1) | CA3151641A1 (enExample) |
| IL (1) | IL290247A (enExample) |
| MX (1) | MX2022002096A (enExample) |
| PH (1) | PH12022550306A1 (enExample) |
| WO (1) | WO2021034194A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240207457A1 (en) * | 2021-05-11 | 2024-06-27 | The Catholic University Of Korea Industry-Academic Cooperation Foundation | Cancer-specific polypeptide and use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| EP1286671B1 (en) * | 2000-05-15 | 2006-04-05 | Celgene Corporation | Compositions for the treatment of colorectal cancer comprising thalidomide and irinotecan |
| DK2059533T3 (da) | 2006-08-30 | 2013-02-25 | Genentech Inc | Multispecifikke antistoffer |
| RU2731084C2 (ru) | 2008-06-27 | 2020-08-28 | Мерюс Н.В. | Продуцирующие антитела млекопитающие, не являющиеся человеком |
| SG10201402742YA (en) | 2009-03-20 | 2014-08-28 | Genentech Inc | Bispecific anti-her antibodies |
| US20120045433A1 (en) * | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
| DK2838918T3 (da) | 2012-04-20 | 2019-08-12 | Merus Nv | Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler |
| EP3786186A1 (en) | 2014-02-28 | 2021-03-03 | Merus N.V. | Antibodies that bind egfr and erbb3 |
| AU2016293942B2 (en) | 2015-07-10 | 2022-06-16 | Merus B.V. | Human CD3 binding antibody |
| WO2017069628A2 (en) * | 2015-10-23 | 2017-04-27 | Merus N.V. | Binding molecules that inhibit cancer growth |
| KR20180138205A (ko) * | 2016-03-22 | 2018-12-28 | 바이오노믹스 리미티드 | 항-lgr5 단클론성 항체의 투여 |
-
2020
- 2020-08-19 US US17/632,181 patent/US20230084382A1/en active Pending
- 2020-08-19 WO PCT/NL2020/050517 patent/WO2021034194A2/en not_active Ceased
- 2020-08-19 AU AU2020331879A patent/AU2020331879C1/en active Active
- 2020-08-19 CN CN202080058714.1A patent/CN114555115A/zh active Pending
- 2020-08-19 KR KR1020227008659A patent/KR20220048015A/ko active Pending
- 2020-08-19 BR BR112022003143A patent/BR112022003143A2/pt unknown
- 2020-08-19 JP JP2022511055A patent/JP7536085B2/ja active Active
- 2020-08-19 EP EP20758359.2A patent/EP4017879A2/en active Pending
- 2020-08-19 CN CN202210968392.5A patent/CN116333154A/zh active Pending
- 2020-08-19 MX MX2022002096A patent/MX2022002096A/es unknown
- 2020-08-19 CA CA3151641A patent/CA3151641A1/en active Pending
- 2020-08-19 PH PH1/2022/550306A patent/PH12022550306A1/en unknown
-
2022
- 2022-01-30 IL IL290247A patent/IL290247A/en unknown
-
2024
- 2024-03-19 JP JP2024043606A patent/JP2024075676A/ja active Pending